-+ 0.00%
-+ 0.00%
-+ 0.00%

IPO News | Jingze Biotech's second listing on the Hong Kong Stock Exchange

Zhitongcaijing·01/02/2026 00:25:02
Listen to the news

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on December 31, Jingze Biopharmaceuticals (Hefei) Co., Ltd. (abbreviation: Jingze Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, with CICC and Guoyuan International as co-sponsors. The company filed a statement with the Hong Kong Stock Exchange on June 27, 2025. According to the prospectus, Jingze Biotech is a biopharmaceutical company focusing on the two major tracks of assisted reproductive drugs and ophthalmic drugs. The company has two core products, including JZB30, a registered recombinant human follicle-stimulating hormone (rhFSH) injection, and JZB05 is a candidate drug candidate for anti-vascular endothelial growth factor (VEGF) vitreous injection. In addition, the company also has six pipeline products.

image.png